AL-S Pharma AG
Zurich, Zurich, Switzerland · Biotechnology, Health Care, Pharmaceutical
AL-S Pharma is a Swiss-based single-asset company focused on developing AP-101 for treating amyotrophic lateral sclerosis (ALS). It was co-created by Neurimmune and TVM Capital Life Science. The company leverages a network of ALS experts to execute its innovative clinical plans. AL-S Pharma is committed to advancing the clinical development of therapies targeting misfolded SOD1.
Key facts
- Headquarters
- Zurich, Zurich, Switzerland
- Employees
- 11
- Industries
- Biotechnology, Health Care, Pharmaceutical
- Status
- Private
- Website
- al-spharma.com
- Company page
Recent activity at AL-S Pharma AG
Leadership
- Harry Welten, Chief Executive Officer
Verified email and direct lines for AL-S Pharma AG’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
AL-S Pharma AG in the news
- AL-S Pharma Presents AP-101 Phase 2 Data Supporting Misfolded SOD1 as a Therapeutic Target in ALS at ENCALS 2026 - Business Wire (Jun 24, 2026)
- AL-S Pharma Appoints Harry Welten as Chief Executive Officer - News-Press NOW (Oct 14, 2026)
- AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study - PR Newswire (Dec 05, 2025)
- Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS - Business Wire (Mar 19, 2026)
- AL-S Pharma announces positive topline results from Phase 2 study of AP-101 for the treatment of amyotrophic lateral sclerosis (ALS) - PR Newswire (Sep 04, 2025)
Companies similar to AL-S Pharma AG
- Ensho Therapeutics · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Lighthouse Pharmaceuticals · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Verdiva Bio · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Kenox Pharmaceuticals · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Matisse Pharmaceuticals B.V · Biotechnology, Health Care, Pharmaceutical, Therapeutics
About AL-S Pharma AG: questions and answers
What does AL-S Pharma AG do?
AL-S Pharma is a Swiss-based single-asset company focused on developing AP-101 for treating amyotrophic lateral sclerosis (ALS). It was co-created by Neurimmune and TVM Capital Life Science. The company leverages a network of ALS experts to execute its innovative clinical plans. AL-S Pharma is committed to advancing the clinical development of therapies targeting misfolded SOD1.
Where is AL-S Pharma AG headquartered?
AL-S Pharma AG is headquartered in Zurich, Zurich, Switzerland.
How many employees does AL-S Pharma AG have?
AL-S Pharma AG has about 11 employees.
Who leads AL-S Pharma AG?
Harry Welten is a Chief Executive Officer at AL-S Pharma AG.
What is the latest news on AL-S Pharma AG?
On Oct 14, 2026, AL-S Pharma Appoints Harry Welten as Chief Executive Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy